BioMarin
Manufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
770 Lindaro St, San Rafael, California, ...Phone Number
(415) 506-6700Website
www.biomarin.comRevenue
$3.2 BillionStock Symbol
BMRNIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
10
10
1
2
2
2
About BioMarin
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplaRead more
BioMarin Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMarin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once BioMarin has new funding data
Check out if BioMarin is spiking on competitors!
Earning: See what the market has to say on BioMarin recently announced quarterly report
BioMarin, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BioMarin has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BioMarin launches new products
Click to see if BioMarin had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioMarin
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to BioMarin
Compare insights from companies similar to BioMarin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$673M
1K - 5K
Public
$1.6B
2010
AM
Alyssa MooreChief of Staff and Head Senior Vice President, Program and Portfolio Management
Company Profile Activity
Activity Insights
BioMarin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioMarin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioMarin.
BioMarin financials insights
Gather financial insights about BioMarin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1999
Stock Offering
$58.5M
BioMarin Tech Stack
A closer look at the technologies used by BioMarin
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Open Position
Open Position
Open Position
BioMarin News & Media
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best low priced stocks to buy for the next 3 years. On May 18, BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met only one of its two co-primary endpoints. Treatment led to statistically significant increases in plasma inorganic pyrophosphate/PPi concentration […]BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height...BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in...Evercore ISI Lifts PT on BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best healthcare stocks to buy for the long term. Evercore ISI lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $120 from $110 on May 5, reaffirming an Outperform rating on the shares. In a separate development, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced on May 2 new […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMarin
Sign Up For FreeTo access detailed company insights
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acet... Read More
